A1 Refereed original research article in a scientific journal
Association between post-COVID-19 neuropsychiatric symptoms and persistent glial activation in the limbic system: a TSPO PET study; 
Authors: Tuomaala, Joel; Saraste, Maija; Smith, Emma; Kuusi, Matilda; Westerberg, Elisabet; Honkonen, Eveliina; Kargar, Rahim; Laaksonen, Sini; Lehto, Jussi; Luoma, Amelie; Matilainen, Markus; Misin, Olavi; Atosuo, Janne; Kanerva, Mari; Liira, Helena; Laakso, Sini; Posharina, Tatiana; Saunavaara, Virva; Wahlroos, Saara; Rajander, Johan; Airas, Laura
Publisher: Springer Science and Business Media LLC
Publication year: 2026
Journal: Journal of Neurology
Article number: 298
Volume: 273
ISSN: 0340-5354
eISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-026-13842-w
Publication's open availability at the time of reporting: Open Access
Publication channel's open availability : Partially Open Access publication channel
Web address : https://doi.org/10.1007/s00415-026-13842-w
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/523815324
Self-archived copy's licence: CC BY
Self-archived copy's version: Publisher`s PDF
Background: A subset of individuals experience prolonged neurological and psychiatric symptoms following SARS-CoV-2 infection, a condition referred to as long COVID (LC). Limited evidence implicates ongoing neuroinflammatory processes as a driver of LC. This study investigates neuroinflammation in LC using translocator protein positron emission tomography (TSPO PET).
Methods: 14 LC, 11 healthy control (HC) and 13 multiple sclerosis (MS) participants were included in the study. They underwent [11C]PK11195 TSPO PET and 3T magnetic resonance imaging (MRI) to evaluate glial activation, white matter (WM) pathology and brain volumetrics. Serum neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) were measured as markers of neuronal and glial damage. LC participants completed neurological examinations and mental health assessments.
Results: TSPO availability, measured as distribution volume ratio (DVR), was not elevated in LC compared to HCs but was significantly lower in LC compared to MS (WM DVR 1.03 vs. 1.06; p = 0.007). Individuals imaged within 16 months of SARS-CoV-2 infection showed higher WM DVR compared to those with a longer disease duration (1.05 vs. 1.02; p = 0.04). Moreover, lower quality of life was associated with higher DVRs in the hippocampus, amygdala and thalamus (ρ = - 0.83- - 0.70), and depression and anxiety correlated positively with DVRs in the hippocampus and amygdala (ρ = 0.75-0.97).
Conclusions: LC TSPO availability did not differ from HCs in any studied brain area. However, lower WM TSPO availability in individuals with longer LC duration suggests COVID-19-associated neuroinflammation may subside with time, while the association between limbic TSPO availability and LC severity may imply a role for limbic activity in LC symptomology.
Downloadable publication This is an electronic reprint of the original article. |
Funding information in the publication:
Open Access funding provided by University of Turku (including Turku University Central Hospital). This work was funded by the Research Council of Finland grant for a clinical researcher (decision number: 330902), Sigrid Juselius Foundation (decision number N/A), Finnish MS Foundation (decision number N/A), Suomen lääketieteen Säätiö (decision number N/A), the InFLAMES Flagship Programme of the Academy of Finland (decision numbers: 374291, 337530, 357910 and 358823), and the European Union’s Horizon Europe research and innovation programme (grant agreement No 101057553).